Vasopressin Doesn't Cut Kidney Failure-Free Days in Septic Shock

This article originally appeared here.
Share this content:
Vasopressin Doesn't Cut Kidney Failure-Free Days in Septic Shock
Vasopressin Doesn't Cut Kidney Failure-Free Days in Septic Shock

WEDNESDAY, Aug. 3, 2016 (HealthDay News) -- Among adults with septic shock, early use of vasopressin does not improve the number of kidney failure-free days versus norepinephrine, according to a study published in the Aug. 2 issue of the Journal of the American Medical Association.

Anthony C. Gordon, M.D., from Imperial College London, and colleagues compared the effect of early vasopressin versus norepinephrine on kidney failure. Adult patients with septic shock requiring vasopressors were enrolled and randomized to vasopressin and hydrocortisone (101 patients), vasopressin and placebo (104 patients), norepinephrine and hydrocortisone (101 patients), or norepinephrine and placebo (103 patients).

The researchers found that 57.0 percent of survivors in the vasopressin group and 59.2 percent in the norepinephrine group never developed kidney failure (difference, −2.3 percent [95 percent confidence interval (CI), −13.0 to 8.5 percent]). For patients who did not survive, who experienced kidney failure, or both, the median number of kidney failure-free days was nine days in the vasopressin group and 13 days in the norepinephrine group (difference, −4 days [95 percent CI, −11 to 5]). The vasopressin group had less use of renal replacement therapy (25.4 versus 35.3 percent; difference, −9.9 percent [95 percent CI, −19.3 to −0.6 percent]). Just over 10 percent (10.7 percent) had a serious adverse event in the vasopressin group compared to 8.3 percent in the norepinephrine group (difference, 2.5 percent [95 percent CI, −3.3 to 8.2 percent]).

"Although these findings do not support the use of vasopressin to replace norepinephrine as initial treatment in this situation, the confidence interval included a potential clinically important benefit for vasopressin, and larger trials may be warranted to assess this further," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »